IBDEI0EW ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7192,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,7192,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,7192,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,7193,0)
 ;;=205.10^^55^577^19
 ;;^UTILITY(U,$J,358.3,7193,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7193,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,7193,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,7193,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,7194,0)
 ;;=205.11^^55^577^21
 ;;^UTILITY(U,$J,358.3,7194,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7194,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,7194,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,7194,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,7195,0)
 ;;=289.0^^55^577^55
 ;;^UTILITY(U,$J,358.3,7195,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7195,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,7195,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,7195,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,7196,0)
 ;;=238.4^^55^577^109
 ;;^UTILITY(U,$J,358.3,7196,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7196,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,7196,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,7196,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,7197,0)
 ;;=V58.61^^55^577^126
 ;;^UTILITY(U,$J,358.3,7197,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7197,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,7197,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,7197,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,7198,0)
 ;;=282.49^^55^577^117
 ;;^UTILITY(U,$J,358.3,7198,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7198,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,7198,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,7198,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,7199,0)
 ;;=289.89^^55^577^15
 ;;^UTILITY(U,$J,358.3,7199,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7199,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,7199,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,7199,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,7200,0)
 ;;=238.79^^55^577^88
 ;;^UTILITY(U,$J,358.3,7200,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7200,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,7200,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,7200,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,7201,0)
 ;;=287.30^^55^577^110
 ;;^UTILITY(U,$J,358.3,7201,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7201,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,7201,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,7201,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,7202,0)
 ;;=288.09^^55^577^8
 ;;^UTILITY(U,$J,358.3,7202,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7202,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,7202,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,7202,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,7203,0)
 ;;=V10.21^^55^577^61
 ;;^UTILITY(U,$J,358.3,7203,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7203,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,7203,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,7203,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,7204,0)
 ;;=284.2^^55^577^106
 ;;^UTILITY(U,$J,358.3,7204,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7204,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,7204,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,7204,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,7205,0)
 ;;=202.40^^55^577^76
 ;;^UTILITY(U,$J,358.3,7205,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7205,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,7205,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,7205,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,7206,0)
 ;;=287.49^^55^577^118
